AstraZeneca announced its drug Ultomiris met a key goal in a Phase III trial for IgA nephropathy, significantly reducing urine protein levels by Week 34. The result marks the first time the complement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results